- Home
- UTSI vs LGVN Comparison
UTSI vs LGVN Comparison
Compare UTSI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTSI
- LGVN
- Stock Information
- Founded
- UTSI 1991
- LGVN 2014
- Country
- UTSI China
- LGVN United States
- Employees
- UTSI N/A
- LGVN N/A
- Industry
- UTSI Telecommunications Equipment
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- UTSI Telecommunications
- LGVN Health Care
- Exchange
- UTSI Nasdaq
- LGVN Nasdaq
- Market Cap
- UTSI 21.6M
- LGVN 23.4M
- IPO Year
- UTSI 2000
- LGVN 2021
- Fundamental
- Price
- UTSI $2.38
- LGVN $1.20
- Analyst Decision
- UTSI
- LGVN Strong Buy
- Analyst Count
- UTSI 0
- LGVN 3
- Target Price
- UTSI N/A
- LGVN $8.67
- AVG Volume (30 Days)
- UTSI 4.0K
- LGVN 123.8K
- Earning Date
- UTSI 07-01-2025
- LGVN 08-13-2025
- Dividend Yield
- UTSI N/A
- LGVN N/A
- EPS Growth
- UTSI N/A
- LGVN N/A
- EPS
- UTSI N/A
- LGVN N/A
- Revenue
- UTSI $10,878,000.00
- LGVN $2,225,000.00
- Revenue This Year
- UTSI N/A
- LGVN N/A
- Revenue Next Year
- UTSI N/A
- LGVN $51.48
- P/E Ratio
- UTSI N/A
- LGVN N/A
- Revenue Growth
- UTSI N/A
- LGVN 127.50
- 52 Week Low
- UTSI $1.84
- LGVN $1.14
- 52 Week High
- UTSI $3.22
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- UTSI 47.87
- LGVN 39.12
- Support Level
- UTSI $2.20
- LGVN $1.26
- Resistance Level
- UTSI $2.42
- LGVN $1.47
- Average True Range (ATR)
- UTSI 0.11
- LGVN 0.09
- MACD
- UTSI -0.01
- LGVN 0.00
- Stochastic Oscillator
- UTSI 56.06
- LGVN 18.18
About UTSI UTStarcom Holdings Corp.
UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.